What are the fundraising trends in the remote patient monitoring market?
In our updated market reports, you will find everything you need
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play remote patient monitoring companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. The sample keeps only companies whose core business is provider-led patient monitoring outside traditional clinical settings, and excludes broad telehealth, home care, diagnostics-only, wellness, and consumer-wearable businesses unless remote patient monitoring is the central product.
The remote patient monitoring market expanded by capital from 2024 to 2025, rising from $196.6M across 11 deals to $254.6M across 10 deals. That increase came from larger rounds rather than more companies raising money, because deal count fell slightly while the average and median round sizes increased.
The freshest 2026 signal is not broad acceleration. Through July 2026, the market raised $153.1M across 6 deals, compared with $158.3M across 4 deals over the comparable period in 2025. So far in 2026, deal count is higher, but capital is essentially flat to slightly down.
Capital in the remote patient monitoring market is becoming more concentrated. The largest round accounted for 24.4% of 2024 funding, 39.3% of 2025 funding, and 65.3% of year-to-date 2026 funding, which means annual totals increasingly depend on one or two scaled companies.
Later-stage companies are taking most of the dollars. Series B and later plus growth rounds represented 66.1% of 2024 capital, 62.1% of 2025 capital, and 80.4% of year-to-date 2026 capital. That makes the market look more like a selective scale-up market than a broad formation-stage market.
New startup formation is limited in the disclosed public sample. First financings represented 9.1% of deals in 2024, 10.0% in 2025, and 0.0% in year-to-date 2026. Investors are mostly backing companies with prior traction, regulatory progress, provider deployments, or commercial evidence.
Subcategory leadership is rotating. Care Coordination Software led 2024 capital because of CoachCare, Remote Cardiac Monitoring led 2025 capital because of VitalConnect and WearLinq, and Chronic Care Monitoring dominates year-to-date 2026 because of Cadence and Sêmeia.
North America is becoming more dominant by capital. Its share rose from 53.6% in 2024 to 75.4% in 2025 and 84.9% in year-to-date 2026. Europe remains strategically relevant, but the largest recent growth rounds have been North American.
The investor base is broad but not repeat-heavy. No disclosed investor appeared in more than one qualifying deal in 2024, 2025, or year-to-date 2026. That suggests company-specific conviction rather than a tightly organized specialist RPM investor cluster.
The practical interpretation is that the remote patient monitoring market is maturing around proof. The strongest funding signals attach to companies that convert remote data into clinical action, workflow relief, reimbursement logic, or health-system adoption rather than companies that merely collect patient data.
Is more or less capital going into the remote patient monitoring market?
More capital went into the remote patient monitoring market on a full-year basis from 2024 to 2025, but the freshest 2026 signal is flat to slightly down and heavily concentrated. Full-year disclosed capital rose from $196.6M in 2024 to $254.6M in 2025, an increase of about 30%, while year-to-date 2026 funding through July was $153.1M versus $158.3M over the comparable period in 2025.
The full-year comparison is the cleaner structural read because it compares two complete years. The remote patient monitoring market attracted more dollars in 2025 even though it had fewer deals, which means investors were willing to write larger checks into selected companies rather than expand the number of funded companies.
The current-year comparison is useful because it shows that the 2025 increase has not clearly continued. Through July 2026, the remote patient monitoring market had 6 qualifying deals, compared with 4 over the comparable period in 2025, but total capital was slightly lower. So the market is not collapsing, but it is also not showing broad capital acceleration.
The most important caveat is concentration. In 2024, the largest round accounted for 24.4% of annual capital. In 2025, VitalConnect's $100M financing accounted for 39.3%. In year-to-date 2026, Cadence's $100M Series C accounted for 65.3%. That means headline funding totals increasingly depend on one very large company per period.
The practical answer is that more capital went into the remote patient monitoring market in 2025 than in 2024, but 2026 so far does not confirm another step up. The better reading is selective resilience: investors still fund high-conviction RPM companies, but broad category-wide capital expansion is not yet visible.
Is remote patient monitoring funding activity driven by more deals or larger rounds?
Remote patient monitoring funding activity is being driven more by larger rounds than by more deals on the full-year comparison. Deal count fell from 11 in 2024 to 10 in 2025, while total capital rose from $196.6M to $254.6M, so the increase came from round size rather than deal breadth.
The average round rose from $17.9M in 2024 to $25.5M in 2025. The median round also rose from $11.0M to $17.8M, which means the increase was not only a single outlier effect. A typical qualifying RPM round was larger in 2025 than in 2024.
That said, the market still depends heavily on top deals. Excluding the largest deal, 2025 capital falls from $254.6M to $154.6M, which is below the full-year 2024 total. So larger rounds drove the increase, but the largest financing did a lot of the work.
The freshest 2026 comparison looks different. Through July 2026, the market had 6 deals versus 4 over the comparable 2025 period, but capital was slightly lower at $153.1M versus $158.3M. That means current-year activity is more deal-count-driven, while the capital base remains distorted by Cadence's $100M round.
The best interpretation is that the remote patient monitoring market is bifurcated. The full-year 2025 expansion was driven by larger rounds, while 2026 so far has more deals but lower typical round strength once the largest financing is separated from the rest of the market.
Is remote patient monitoring capital moving toward later-stage or earlier-stage companies?
Remote patient monitoring capital is moving toward later-stage companies by dollars, even though Series A rounds still make up a meaningful share of deal count. Series B and later plus growth rounds captured 66.1% of 2024 capital, 62.1% of 2025 capital, and 80.4% of year-to-date 2026 capital.
The 2025 stage mix shows why deal count alone can mislead. Series A rounds represented 70.0% of 2025 deals, but only 38.0% of capital. VitalConnect's single Series D+ financing was larger than the combined total of the seven Series A deals.
The year-to-date 2026 stage mix is even more later-stage by capital. Cadence's $100M Series C and Sêmeia's approximately $23.1M growth round together account for $123.1M, or 80.4% of all disclosed qualifying capital through July. Seed plus Series A rounds account for only $28.5M.
This does not mean early-stage RPM is dead. The market still had Series A and seed financings in 2025 and 2026. But the largest pools of capital are reserved for companies with existing deployments, commercial evidence, health-system relationships, regulated monitoring infrastructure, or reimbursement logic.
The remote patient monitoring market is therefore later-stage by conviction and earlier-stage only by residual activity. Investors are still taking some early bets, but the dominant dollars are moving toward companies that have already cleared earlier proof hurdles.
Is the remote patient monitoring market maturing or still experimental?
The remote patient monitoring market is maturing, not still broadly experimental. The clearest evidence is that first financings are rare, follow-on rounds dominate capital, and the largest rounds go to companies with regulatory credibility, provider integration, clinical workflows, or health-system partnerships.
In 2024, only 1 of 11 deals was a first financing, representing 9.1% of deal count and 5.9% of capital. In 2025, only 1 of 10 deals was a first financing, representing 10.0% of deal count and 7.9% of capital. In year-to-date 2026, none of the 6 qualifying disclosed deals was a first financing.
The stage mix points in the same direction. Later-stage and growth rounds captured about two-thirds of capital in both 2024 and 2025, then rose to 80.4% of year-to-date 2026 capital. That is not the pattern of a category dominated by fresh company formation.
The product evidence also looks mature. The largest rounds are attached to companies that monitor chronic disease, cardiac patients, virtual wards, respiratory disease, oncology pathways, maternal risk, urology, glucose, or multi-pathology outpatient follow-up. The common thread is not novelty; it is clinical integration.
The best description is selectively scaling. The remote patient monitoring market is still innovative, but investors now expect proof that remote monitoring fits into provider workflow, reimbursement, patient management, and clinical action.
Are new startups still entering the remote patient monitoring market?
New startups are still entering the remote patient monitoring market, but they are not the main funding story. The disclosed public evidence shows very few first financings: one in 2024, one in 2025, and zero in year-to-date 2026.
The first-financing share stayed around 9% to 10% in full-year 2024 and 2025, then fell to 0.0% in the 2026 period through July. That is a strong signal that investors are mostly supporting known companies rather than launching a new wave of RPM startups.
The measured public dataset probably understates true formation activity. Some relevant companies announced funding without amounts, and some small seed rounds, SAFEs, grants, or accelerator financings may not appear in public sources. But those invisible or undisclosed financings cannot support dollar-based conclusions.
The investable public signal is clear: the remote patient monitoring market is no longer a low-barrier formation market. New entrants need a clinical wedge, a provider-led workflow, credible data capture, and a path to reimbursement or buyer adoption.
So yes, new RPM startups can still enter the market, but the market is now biased toward companies that can prove they will become part of healthcare operations rather than just add another data stream.
Are more investors entering the remote patient monitoring market?
There is no strong evidence that more investors are entering the remote patient monitoring market in a broad, repeatable way. The market has many named investors, but no disclosed investor appeared in more than one qualifying deal in 2024, 2025, or year-to-date 2026.
The raw investor counts show breadth but not a clean expansion trend. The 2024 sample had approximately 56 disclosed investors including angels. The 2025 sample had approximately 37 named investors. The year-to-date 2026 sample had approximately 30 named disclosed investors. Those numbers are affected by disclosure style, deal count, and angel participation, so the better signal is repeat activity.
The absence of repeat investors is striking. If more investors were entering the remote patient monitoring market as a coherent category thesis, some investors would likely show up across multiple deals in the same year. That did not happen in any of the three analyzed periods.
Tier-1 participation is present but selective. General Catalyst, Lakestar, Sands Capital, Comcast Ventures, Balderton, Exor, UPMC Enterprises, Labcorp, Ally Bridge Group, EW Healthcare Partners, Spark Capital, Thrive Capital, Coatue, B Capital, Threshold Ventures, and Felicis Ventures all appear around specific deals, but the activity is not broad enough to show a dedicated RPM investor cluster.
The better interpretation is that investor interest is episodic and company-specific. Serious investors are entering individual RPM rounds when the proof is strong, but the category is not yet seeing a wave of repeat specialist capital.
Are top investors getting more or less active in remote patient monitoring?
Top investors are getting more selective in the remote patient monitoring market, not more active in a broad repeated way. High-quality investors continue to appear in major rounds, but the absence of repeat investors within each period shows that top investors are not systematically increasing the number of RPM bets.
In 2024, strong investors appeared in rounds for HealthSnap, SAVA, Doccla, Impilo, and CoachCare. In 2025, strong investors appeared in VitalConnect, Percipio, Sibel, Sava, RDS, Brook.ai, WearLinq, and Liom. In year-to-date 2026, Spark Capital, Thrive Capital, General Catalyst, Coatue, B Capital, Threshold Ventures, and Felicis Ventures appeared in the screened sample.
The top-investor signal is strongest around platform-scale or technically differentiated companies. General Catalyst appears in Doccla in 2024 and Cadence in 2026, and Balderton appears around SAVA/Sava across 2024 and 2025. But within each annual period, no named investor appears in more than one qualifying deal.
That means top investors are acting as validators, not market makers. A marquee investor on a remote patient monitoring deal should be read as a strong signal about that company, not as proof that the entire category has entered a broad funding boom.
The practical conclusion is that top investors are less scattershot and more proof-driven. They are present where clinical workflow, regulatory credibility, health-system adoption, or scaled chronic-care economics are visible.
Which remote patient monitoring subcategories are gaining momentum?
Chronic Care Monitoring is gaining the clearest current momentum in the remote patient monitoring market, while Remote Cardiac Monitoring, Diabetes Monitoring, and Monitoring Data Analytics show selective momentum in specific periods. Through July 2026, Chronic Care Monitoring captured $133.1M, or 86.9% of capital, across 4 of 6 qualifying deals.
The current Chronic Care Monitoring signal is powerful but concentrated. Cadence's $100M Series C is the largest 2026 deal so far, and Sêmeia's approximately $23.1M growth round adds a second scaled platform signal. Salvo Health and Noctem Health broaden the category, but the capital dominance is still led by Cadence.
The full-year 2025 comparison points to Remote Cardiac Monitoring as the previous momentum leader. Remote Cardiac Monitoring captured $114.0M in 2025, or 44.8% of annual capital, driven by VitalConnect and WearLinq. That was a major change from 2024, when no pure-play Remote Cardiac Monitoring deal was counted.
Diabetes Monitoring also gained visibility in 2025 after being absent in 2024. Sava Technologies and Liom together contributed about $35.3M, both in Europe and both around next-generation sensing. That suggests investor interest in diabetes monitoring is more sensor-breakthrough-oriented than generic software-management-oriented.
The strongest answer is that Chronic Care Monitoring is the freshest momentum category, Remote Cardiac Monitoring was the strongest full-year 2025 mover, and Diabetes Monitoring plus Monitoring Data Analytics remain promising but not yet broad enough to call full funding waves.
Which remote patient monitoring subcategories are losing momentum?
Hospital at Home Platforms have the clearest visible loss of momentum in the remote patient monitoring market. The category had Doccla's $46M Series B in 2024, equal to 23.4% of annual capital, but no qualifying disclosed deal in 2025 and no qualifying disclosed deal in year-to-date 2026.
That does not mean hospital-at-home demand has disappeared. It means pure-play hospital-at-home platform funding is not showing up in the disclosed RPM equity sample after Doccla's 2024 round. Some hospital-at-home activity may be inside health systems, broader care-at-home platforms, or companies that do not pass the strict pure-play screen.
Connected Vital Devices also lost visible current-year momentum. The category had $16.8M across 2 deals in 2024 and $38.3M across 2 deals in 2025, led by Sibel Health and Dozee. Through July 2026, it had no counted qualifying deal.
Wearable Health Monitoring remains episodic rather than accelerating. SAVA raised $8M in 2024 and RDS raised about $16.6M in 2025, but there was no qualifying year-to-date 2026 deal. The category remains investable, but it is not producing steady deal flow.
Care Coordination Software has also lost the prominence it had in 2024. CoachCare drove the category to $64M in 2024, but the category had no counted 2025 deal and only Malama Health's estimated $6M equity component in year-to-date 2026.
Which regions are gaining momentum in remote patient monitoring funding?
North America is gaining the clearest capital momentum in remote patient monitoring funding. North America's share of capital rose from 53.6% in 2024 to 75.4% in 2025 and 84.9% in year-to-date 2026.
The deal-count signal also favors North America in the freshest period. Through July 2026, North America accounted for 5 of 6 qualifying deals, or 83.3% of deal count. That compares with 50.0% of full-year 2025 deals and 54.5% of full-year 2024 deals.
The North American gain is partly driven by large rounds. VitalConnect's $100M financing in 2025 and Cadence's $100M Series C in 2026 heavily shape the regional capital split. Without Cadence, North America's year-to-date 2026 capital would be $30M instead of $130M.
Still, the regional direction is clear. The largest recent remote patient monitoring rounds are tied to North American companies, where reimbursement, provider economics, health-system partnerships, and chronic-care infrastructure are especially important funding drivers.
Europe remains credible but less dominant by capital. Its companies continue to appear in virtual wards, glucose sensing, wearable patches, and multi-pathology monitoring, but the region has not matched North America's recent $100M-scale financings.
Which regions are losing momentum in remote patient monitoring funding?
Europe and Asia-Pacific are losing visible momentum relative to North America in remote patient monitoring funding, but the interpretation is different for each region. Europe is losing capital share, while Asia-Pacific is losing visible deal continuity under the strict public-equity screen.
Europe's capital share fell from 42.9% in 2024 to 21.3% in 2025 and 15.1% in year-to-date 2026. That is a clear decline in capital share. However, Europe still produced 4 deals in 2024, 4 deals in 2025, and one meaningful Sêmeia growth round in year-to-date 2026.
So Europe's decline should not be read as disappearance. It should be read as North America pulling ahead on large growth rounds. Europe still has credible companies, especially in virtual ward infrastructure, connected patches, glucose monitoring, and outpatient multi-pathology monitoring.
Asia-Pacific is thinner. Aevice Health contributed one $7M deal in 2024, Dozee contributed one $8.3M mixed financing in 2025, and no qualifying Asia-Pacific deal appeared through July 2026. That does not mean demand is weak, but it does mean the region is not yet producing a visible sequence of disclosed pure-play RPM equity rounds.
Latin America, the Middle East, and Africa are absent from the qualifying disclosed sample across the analyzed periods. Those absences may reflect venture visibility and strict inclusion criteria, but they still mean these regions are not yet measurable RPM funding centers in the public data.
Is the remote patient monitoring market becoming more global or more regionally concentrated?
The remote patient monitoring market is becoming more regionally concentrated by capital, even though clinical need and product innovation remain international. North America's capital share rose from 53.6% in 2024 to 75.4% in 2025 and 84.9% in year-to-date 2026.
The deal-count picture is less extreme but still points toward current concentration. North America represented 54.5% of 2024 deals, 50.0% of 2025 deals, and 83.3% of year-to-date 2026 deals. Europe moved from 36.4% of 2024 deals and 40.0% of 2025 deals to only 16.7% in year-to-date 2026.
The market is therefore not becoming more global in funding terms. It is becoming more North America-heavy, especially for large rounds. The biggest recent growth financings are concentrated in the United States.
The caveat is that Europe remains an important innovation base. Doccla, SAVA, Sava Technologies, RDS, Liom, Resilience, Minze Health, Wanda Health, and Sêmeia show that remote patient monitoring company formation is not purely North American. The capital map is more concentrated than the company map.
The best interpretation is that the remote patient monitoring market is global in clinical relevance, transatlantic in product innovation, and North America-led in venture capital intensity.
Is remote patient monitoring capital moving toward proven winners or new opportunities?
Remote patient monitoring capital is moving toward proven winners rather than new opportunities. Follow-on rounds represented 10 of 11 deals in 2024, 9 of 10 deals in 2025, and all 6 qualifying deals in year-to-date 2026.
The capital split is even clearer. Follow-on rounds accounted for 94.2% of capital in 2024, 92.2% in 2025, and 100.0% in year-to-date 2026. First financings have not been a meaningful source of capital in any analyzed period.
The later-stage tilt confirms the same pattern. Series B and later plus growth rounds captured 66.1% of 2024 capital, 62.1% of 2025 capital, and 80.4% of year-to-date 2026 capital. Investors are putting their largest checks into companies that already have proof, not companies that only have a concept.
The phrase proven winner should be interpreted carefully. In remote patient monitoring, proof does not necessarily mean profitability or public-company scale. It often means regulatory clearance, clinical-grade monitoring, patient deployment, health-system partnerships, reimbursement logic, or a workflow that providers can actually use.
The practical takeaway is that new opportunities can still be funded, but they are not receiving the market's largest dollars. The remote patient monitoring market is allocating capital toward companies that already look like healthcare infrastructure.
Is the remote patient monitoring market becoming winner-takes-most?
The remote patient monitoring market is becoming winner-takes-most by capital, but not winner-takes-all by company count. Each year still includes multiple funded companies, but the largest rounds are capturing a growing share of total dollars.
In 2024, the top deal captured 24.4% of capital and the top 3 captured 60.5%. In 2025, the top deal captured 39.3% and the top 3 captured 62.1%. In year-to-date 2026, the top deal captured 65.3% and the top 3 captured 89.6%.
The bottom half of deals also shows growing inequality. The bottom 50% of 2024 deals captured 15.3% of capital. The bottom 50% of 2025 deals captured 22.6%. In year-to-date 2026, the bottom half captured only 10.4%.
This means the current market is extremely concentrated by dollars. Cadence alone accounts for nearly two-thirds of year-to-date 2026 funding. But smaller companies still raised across chronic care, cardiac monitoring, and care coordination, so the market is not closed to non-leaders.
The right phrase is winner-takes-most-capital. The remote patient monitoring market still supports multiple models, but the majority of dollars are increasingly reserved for companies investors believe can become scaled provider infrastructure.
Is the next wave of remote patient monitoring winners becoming visible?
The next wave of remote patient monitoring winners is becoming visible, but the visibility is selective rather than broad. The strongest emerging winners are companies that combine remote data capture with clinician workflow, reimbursement logic, regulated monitoring, and proof of deployment.
Cadence is the clearest current winner signal. Its $100M Series C in year-to-date 2026 suggests that investors see chronic-disease RPM as a scalable operating layer for health systems and older adults. Sêmeia is another high-signal company because its growth round is tied to multi-pathology remote monitoring and large-scale facility deployment.
Remote Cardiac Monitoring also has visible winner candidates. VitalConnect's $100M 2025 financing and WearLinq's $14M cardiac-monitoring equity round show that investors still value regulated, high-acuity, clinically specific monitoring use cases.
Connected device and sensing companies are also part of the next wave, but only where the technical claim is strong. Sibel Health, RDS, Sava Technologies, and Liom all point to a future where clinical-grade wearables, connected patches, and glucose or metabolic sensing can attract capital if they are clinically differentiated.
The weaker profile is also becoming visible. Broad virtual care, generic monitoring dashboards, consumer wellness wearables, and care coordination without a monitored clinical-risk loop are less likely to define the next wave of winners.
Is the remote patient monitoring funding landscape fragmenting or consolidating?
The remote patient monitoring funding landscape is consolidating by capital but fragmenting by investors and product theses. The largest rounds are taking more of the dollars, while investor syndicates and subcategory leadership remain dispersed.
The consolidation signal is obvious in top-round concentration. The top 3 deals captured 60.5% of 2024 capital, 62.1% of 2025 capital, and 89.6% of year-to-date 2026 capital. The single largest deal's share rose from 24.4% to 39.3% to 65.3% across the same periods.
The fragmentation signal is investor behavior. No named investor appeared in more than one qualifying deal in 2024, 2025, or year-to-date 2026. A consolidated investor landscape would show repeated bets by the same firms; this market does not.
The subcategory picture is also fragmented. Care Coordination Software led capital in 2024, Remote Cardiac Monitoring led in 2025, and Chronic Care Monitoring leads year-to-date 2026. The leading category changes when a large company in that category raises.
The best description is capital consolidation with thesis fragmentation. Investors agree that only a few companies deserve very large checks, but they have not converged on one subcategory, one product model, or one repeat investor playbook.
Where is investor attention shifting in remote patient monitoring?
Investor attention in the remote patient monitoring market is shifting toward provider-integrated chronic-care platforms, regulated monitoring infrastructure, and specialty-specific workflows that convert patient data into action. The shift is away from generic RPM claims and toward clinical operating systems.
The 2024 market funded a mix of chronic care, care coordination, hospital-at-home, connected devices, and wearables. The 2025 market shifted toward Remote Cardiac Monitoring and clinical sensing, with VitalConnect, WearLinq, Sibel, Sava, Liom, and RDS standing out. The year-to-date 2026 market has shifted sharply toward Chronic Care Monitoring, led by Cadence and Sêmeia.
This movement is not a simple straight-line rotation from one category to another. The remote patient monitoring market is shifting toward whichever RPM model can prove the strongest buyer, clinical, and workflow value in a given period.
The recurring theme is integration. Investors are paying more attention to companies that can fit into cardiology, chronic disease, oncology, respiratory care, maternal care, urology, virtual wards, diabetes, or outpatient follow-up. The question is no longer whether remote data can be collected; the question is what a provider can do with that data.
The strongest reading is that investor attention is moving from monitoring as a feature to monitoring as care infrastructure. The companies getting the most attention combine sensors, software, analytics, clinician workflow, patient engagement, and reimbursement logic.
INSIGHTS
The insights below come from reviewing disclosed equity funding for pure-play remote patient monitoring companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026.
- The remote patient monitoring market is not short of capital; it is short of broadly fundable proof points. Total funding rose from $196.6M in 2024 to $254.6M in 2025 while deal count fell from 11 to 10, which means investors preferred fewer, larger, better-validated bets.
- Any RPM funding total should be read together with the largest-round share. The largest deal captured 24.4% of 2024 capital, 39.3% of 2025 capital, and 65.3% of year-to-date 2026 capital, so headline dollars increasingly overstate the breadth of the market.
- The market has shifted from formation to sorting. First financings represented only 9.1% of deals in 2024, 10.0% in 2025, and 0.0% in year-to-date 2026, which means investors are mostly deciding which existing companies deserve scale capital.
- The most important maturity signal is not the number of Series A rounds; it is the share of capital going to Series B and later companies. Later-stage and growth rounds captured 66.1% of capital in 2024, 62.1% in 2025, and 80.4% in year-to-date 2026.
- Series A deal count can mislead in this market. In 2025, Series A represented 70.0% of deals but only 38.0% of capital, so early-stage frequency overstated where investor conviction was strongest.
- Chronic Care Monitoring is the strongest current category because it connects directly to expensive, recurring provider problems. Its 86.9% capital share in year-to-date 2026 is Cadence-driven, so the signal is conviction in scaled chronic-care operations rather than blanket enthusiasm for every chronic-care startup.
- Remote Cardiac Monitoring is the category where clinical specificity most clearly translates into larger financing. VitalConnect and WearLinq show that investors will fund regulated, high-acuity monitoring where clinical need and reimbursement logic are concrete.
- Diabetes Monitoring reappeared in 2025 after being absent in the 2024 pure-play funding set. Sava Technologies and Liom suggest that diabetes-monitoring venture interest is shifting toward sensing breakthroughs, not ordinary disease-management software.
- Hospital at Home Platforms have lost visible funding momentum after Doccla's 2024 round. The care-at-home thesis may still be strong, but the disclosed funding signal has shifted toward monitoring infrastructure and chronic-care platforms rather than full-stack acute home hospitalization.
- The market increasingly rewards companies that close the loop between data and action. Remote data capture alone is not enough; the strongest rounds are tied to alerts, clinician dashboards, AI workflows, care teams, specialist pathways, or health-system integration.
- Hardware is investable only when it is clinically differentiated or workflow-integrated. Sibel, VitalConnect, WearLinq, RDS, Sava, and Liom all suggest that device-led RPM funding requires regulatory credibility, technical defensibility, or a clearly defined clinical use case.
- Generic virtual care is not enough to pass the market's funding test. The strict RPM screen favors companies where provider-led monitoring is central rather than incidental.
- The regional funding map is becoming more North America-heavy by capital. North America's share rose from 53.6% in 2024 to 75.4% in 2025 and 84.9% in year-to-date 2026, largely because the biggest growth rounds are U.S.-centered.
- Europe remains more important than its current capital share suggests. European companies are visible in virtual wards, wearable patches, glucose sensing, and multi-pathology monitoring, but Europe has not matched North America's $100M-scale rounds in 2026 so far.
- Asia-Pacific has need but not repeat visible funding depth. Aevice in 2024 and Dozee in 2025 show relevant company activity, but the absence of qualifying year-to-date 2026 deals means the region is not yet a consistent public-equity RPM funding center.
- The investor base is broad but not disciplined around a shared RPM thesis. The absence of repeat investors within each period suggests company-specific conviction rather than a small group of category specialists repeatedly validating the same market.
- Top-tier investors are acting as selective validators, not market makers. Spark Capital, Thrive Capital, General Catalyst, Coatue, Balderton, Sands Capital, and others appear around strong companies, but they are not repeatedly funding many RPM startups in the same year.
- Median round size is the better indicator of typical company financing than average round size. In year-to-date 2026, the average round is $25.5M while the median is $11.25M, proving that the typical RPM financing is far smaller than the headline average suggests.
- The most credible RPM companies increasingly look like infrastructure companies rather than feature vendors. Cadence, Sêmeia, HealthSnap, Doccla, CoachCare, VitalConnect, and Sibel all point toward platforms embedded into provider operations.
- The market's biggest bottleneck is not patient-data generation; it is provider adoption and workflow capacity. Investors appear to reward companies that reduce clinician burden, automate escalation, integrate into care pathways, or align with reimbursement.
- The strongest future winners are likely to combine clinical-grade monitoring, longitudinal patient engagement, and provider economics. Pure sensors, pure dashboards, or pure AI analytics are weaker unless they create measurable clinical action.
- The most useful forecasting rule is to discount broad RPM claims and overweight evidence of deployment scale. Patient counts, facility counts, regulatory status, health-system partnerships, and specialty workflow integration are more predictive than generic AI, wearable, or virtual-care language.
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this remote patient monitoring funding tracker by reviewing publicly disclosed equity rounds raised by pure-play remote patient monitoring companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to devices or software that let healthcare providers monitor patients outside traditional clinical settings.
We applied four filters to build the dataset. First, we only included disclosed equity rounds or equity-estimable financing components, so grants, debt-only financings, acquisitions, public-company financings, and undisclosed-amount rounds are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play remote patient monitoring companies, which means we excluded broad telehealth, primary care, senior care, home care, diagnostics, wellness, consumer wearables, and therapy-first companies unless provider-led monitoring was the core product. Fourth, every included deal had to be confirmed by a direct company announcement, investor announcement, press release, tier-1 media report, specialist healthcare outlet, or relevant regional publication.
The categories used in the tracker are Connected Vital Devices, Chronic Care Monitoring, Hospital at Home Platforms, Wearable Health Monitoring, Remote Cardiac Monitoring, Diabetes Monitoring, Care Coordination Software, and Monitoring Data Analytics. When a round included debt, grants, or other non-equity components, those amounts were excluded where the equity portion was disclosed or could be reasonably separated; where the split was not fully disclosed, the limitation is noted in the underlying deal review. Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics and make average, median, concentration, and category-share calculations unreliable.
Related blog posts
- The startups that have raised the most funding in the remote patient monitoring market
- The most highly valued startups in the remote patient monitoring market
- How healthy is startup funding in the remote patient monitoring market right now?
